{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-033507","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2025-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.617504+00:00","generated_at":"2026-05-25T09:55:16.084451+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fate Therapeutics: $306.7M cash runway through YE26; FT819 Phase 1 dose expansion in SLE underway","bullets":["Cash, cash equivalents and investments of $306.7M; projected operating runway through year-end 2026.","Initiated Phase 1 dose expansion of FT819 CAR T in SLE with flu-free conditioning (bendamustine or cyclophosphamide alone).","First SLE patient treated with FT819 as add-on to maintenance therapy without conditioning; no DLTs, CRS, or ICANS.","Completed Type D meeting with FDA to allow FT819 expansion into AAV, IIM, SSc; multi-dose and re-treatment permitted.","Q4 total operating expenses $63.6M, including $14.7M non-cash impairment; revenue $1.9M from Ono collaboration."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-033507","json":"https://secwatch.observer/filing/0000950170-25-033507.json","markdown":"https://secwatch.observer/filing/0000950170-25-033507.md","text":"https://secwatch.observer/filing/0000950170-25-033507.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000095017025033507/0000950170-25-033507-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000095017025033507/fate-20250305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T09:55:16.084451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}